ERROR: The request could not be satisfiedDatopotamab deruxtecan met dual primary endpoint of progression-free survival in patients with advanced non-small cell lung cancer in TROPION-Lung01 Phase III trial - AstraZeneca astrazeneca.com Submitted by astrazenecacom1757 on July 3, 2023 at 1:30 AM in business No comments 49